CASI Pharmaceuticals
CASI
CASI was delisted on the 25th of February, 2026.
29 hedge funds and large institutions have $2.45M invested in CASI Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 3 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
4% less capital invested
Capital invested by funds: $2.56M → $2.45M (-$115K)
6% less funds holding
Funds holding: 31 → 29 (-2)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$19.6K |
| 2 |
WSC
Wellington Shields & Co
New York
|
+$17.7K |
| 3 |
Renaissance Technologies
New York
|
+$9.55K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$3.34K |
| 5 |
BIM
BlackRock Investment Management
Wilmington,
Delaware
|
+$636 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$17.7K |
| 2 |
Goldman Sachs
New York
|
-$5.96K |
| 3 |
WSCM
Wellington Shields Capital Management
New York
|
-$4.54K |
| 4 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
-$988 |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$593 |
CASI Hedge Fund Activity: Q3 2016 in Review
29 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q3 2016, worth a combined $2.45M — down 4.5% from $2.56M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of CASI and 1 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 7 added.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $19.6K. The largest seller was Vanguard Group, cutting an estimated $17.7K.
- 29 institutional investors held CASI Pharmaceuticals (CASI) as of Q3 2016, down from 31 in Q2 2016.
- Funds reported $2.45M of CASI Pharmaceuticals stock for Q3 2016, down 4.5% quarter-over-quarter.
- 1 fund opened new CASI Pharmaceuticals positions in Q3 2016 and 3 closed out, a net change of -2 holders.
- The largest CASI Pharmaceuticals buyer in Q3 2016 was Citadel Advisors, an estimated $19.6K added.
- The largest CASI Pharmaceuticals seller in Q3 2016 was Vanguard Group, an estimated $17.7K sold.
Based on aggregated 13F filings for Q3 2016.